Genmab has signed an agreement with Janssen Biotech, Inc. to collaborate exclusively on a next-generation CD38 antibody product, HexaBody®-CD38, incorporating Genmab’s HexaBody technology. The new agreement builds on Genmab’s successful DARZALEX® collaboration with Janssen. HexaBody-CD38 could potentially add to the DARZALEX multiple myeloma franchise and expand the potential of CD38-targeted therapies in further indications. For HexaBody-CD38, Genmab obtained promising pre-clinical data in a panel of multiple myeloma, lymphoma and leukemia models.
“With this agreement, we hope to build upon the successful and productive relationship that we have established with Janssen. As a result of our collaboration, DARZALEX has dramatically improved outcomes for patients with multiple myeloma, yet there are still unmet needs for patients. We are excited that Genmab’s world-class antibody expertise and passion for innovation has led to the novel HexaBody-CD38 product concept. Encouraging pre-clinical data suggest that HexaBody-CD38 could be superior to daratumumab for certain tumor cell types and may expand and extend the promise of CD38-targeted therapies for more patients with multiple myeloma, lymphoma, leukemia, and potentially beyond,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
Breaking News
Genmab, Janssen Partner for Next-Gen CD38 Antibody
To collaborate on HexaBody-CD38, a next-generation CD38 antibody product incorporating Genmab's HexaBody technology
06.12.19
Related Breaking News
-
Collaborations & Alliances | Drug Development | Drug Discovery
Oxford Bio Receives Boehringer Milestone
Advances immuno-oncology programs leveraging the OGAP target discovery platform06.26.19
-
Collaborations & Alliances | Drug Development
3P Biopharmaceuticals and Nordic Nanovector Extend Partnership
For further biopharmaceutical development of Betalutin, a non-Hodgkin lymphoma (NHL) treatment06.25.19
-
Drug Development | Industry News
Rafael Pharma Signs License Agreement with Ono Pharmaceutical
Aims to accelerate development and commercialization of cancer drug candidate CPI-613 (devimistat) in Japan and other Asian countries06.25.19
-
Collaborations & Alliances | Drug Development
PhoreMost and C4X Discovery Announce Collaboration
Collaboration will initially accelerate C4X Discovery’s Parkinson’s disease pipeline06.25.19
-
Clinical Trials | CRO News | Drug Development | Information Technology
Syneos Health Launches New FSP Model
Aims to provide access to a broad range of traditional and non-traditional FSP capabilities to address modern market realities06.24.19
-
Collaborations & Alliances | Drug Development
Loxo Oncology Enters Strategic Pact with AmoyDx, PREMIA
To provide large-scale cancer patient screening in Asia to support the ongoing clinical development of LOXO-29206.24.19
-
Collaborations & Alliances | Drug Development
Amgen and IPD Partner for Drug Research
Covering multiple projects, testing new technologies, and creating protein-building approaches for new medicines06.20.19
-
Collaborations & Alliances | Drug Development
Gilead and Nurix to Collaborate on Novel Therapies
Consisting of targeted protein degradation drugs for patients with cancer and other challenging diseases06.20.19
-
Analytical Services | Breaking News | Drug Development | Drug Discovery | Facilities | Industry News
Concept Life Sciences Opens New Facility
To offer complete pharmaceutical manufacturing support services06.20.19
-
Collaborations & Alliances | Drug Development | Drug Discovery
GSK Partners with University of California for Genomic Research
New ‘Laboratory for Genomics Research’ unites CRISPR pioneers with industry expertise to help unravel mysteries of the human genome06.18.19
-
Drug Development | Drug Discovery | Industry News | Laboratory Testing
Sanofi and Google to Develop Innovation Lab
Virtual healthcare Innovation Lab aims to radically transform how future medicines and health services are delivered06.18.19
-
Drug Development | Industry News
CASI Acquires Anti-CD19 T-cell Therapy from Juventas
In lieu of the upfront payment, CASI Pharmaceuticals (Wuxi) Co., will invest approximately $11.6 million in Juventas06.17.19
-
Collaborations & Alliances | Drug Development
Voyager Therapeutics, Sanofi Genzyme Restructure Gene Therapy Alliance
Voyager gains worldwide rights to VY-HTT01 Huntington’s disease program and ex-U.S. rights to VY-FXN01 Friedreich’s ataxia program for $10 million upfront06.17.19
-
Drug Development | Industry News
Pfizer to Acquire Array BioPharma for $11.4B
Expands innovative biopharma business with multiple targeted investigational cancer therapies and adds a large portfolio of royalty-generating medicines06.17.19
-
Bio News | Breaking News | Drug Development | Industry News
Merck to Acquire Tilos Therapeutics for $773M
Gains portfolio of investigational antibodies modulating TGFβ06.14.19
